期刊
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 24, 期 6, 页码 3303-3313出版社
WILEY
DOI: 10.1111/jcmm.15003
关键词
dracorhodin perchlorate; nuclear factor of activated T cells 1; osteoclast; osteolysis; receptor-activated nuclear factor kappa-B ligand
资金
- National Health and Medical Research Council [APP1107828, APP1127156, APP1163933]
- Inheritance Studio Construction Project of Prestigious TCM Doctors of Guangdong Province [YZYBH[2017]17]
- Guangzhou University of Chinese Medicine [GZYY[2016]83]
- China Scholarship Council [LJF[2018]3101/201808440486]
- National Natural Science Foundation of China [81673999]
- Excellent Doctoral Dissertation Incubation Grant of Guangzhou University of Chinese Medicine [GZYY[2018]62]
Osteolytic skeletal disorders are caused by an imbalance in the osteoclast and osteoblast function. Suppressing the differentiation and resorptive function of osteoclast is a key strategy for treating osteolytic diseases. Dracorhodin perchlorate (D.P), an active component from dragon blood resin, has been used for facilitating wound healing and anti-cancer treatments. In this study, we determined the effect of D.P on osteoclast differentiation and function. We have found that D.P inhibited RANKL-induced osteoclast formation and resorbed pits of hydroxyapatite-coated plate in a dose-dependent manner. D.P also disrupted the formation of intact actin-rich podosome structures in mature osteoclasts and inhibited osteoclast-specific gene and protein expressions. Further, D.P was able to suppress RANKL-activated JNK, NF-kappa B and Ca2+ signalling pathways and reduces the expression level of NFATc1 as well as the nucleus translocation of NFATc1. Overall, these results indicated a potential therapeutic effect of D.P on osteoclast-related conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据